Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$284K Sell
6,140
-456
-7% -$20.9K ﹤0.01% 657
2026
Q2
$216K Buy
6,596
+409
+7% +$14.7K ﹤0.01% 762
2026
Q1
$219K Buy
6,187
+2,340
+61% +$95.2K ﹤0.01% 747
2025
Q4
$156K Sell
3,847
-2,419
-39% -$105K ﹤0.01% 861
2025
Q3
$295K Buy
6,266
+669
+12% +$34.7K ﹤0.01% 675
2025
Q2
$291K Buy
5,597
+457
+9% +$25.1K ﹤0.01% 638
2025
Q1
$310K Buy
5,140
+1,702
+50% +$110K ﹤0.01% 555
2024
Q4
$235K Buy
3,438
+317
+10% +$22.1K ﹤0.01% 587
2024
Q3
$216K Buy
3,121
+653
+26% +$46.1K ﹤0.01% 818
2024
Q2
$198K Buy
2,468
+370
+18% +$27K ﹤0.01% 710
2024
Q1
$168K Buy
2,098
+608
+41% +$54.2K ﹤0.01% 561
2023
Q4
$150K Sell
1,490
-16
-1% -$1.65K ﹤0.01% 539
2023
Q3
$205K Buy
1,506
+1,230
+446% +$141K ﹤0.01% 427
2023
Q2
$29K Sell
276
-3,017
-92% -$368K ﹤0.01% 900
2023
Q1
$292K Buy
3,293
+1,294
+65% +$125K ﹤0.01% 416
2022
Q4
$160K Buy
1,999
+1,388
+227% +$115K ﹤0.01% 530
2022
Q3
$58K Buy
+611
New +$57.6K ﹤0.01% 696

Other funds holding CNMD

Blue Trust's CNMD Position: Q3 2026 in Review

Blue Trust reduced its CONMED (CNMD) stake by 6.9% in Q3 2026, selling an estimated $20.9K and leaving 6,140 shares worth $284K. The position accounts for ﹤0.01% of the portfolio, ranked #657.

Blue Trust first reported a position in CNMD in Q3 2022 and has held it in 17 quarters since. The position peaked at $310K in Q1 2025. 215 funds tracked by Wall St. Rank hold CNMD as of Q3 2026.

  • Blue Trust held 6,140 shares of CONMED worth $284K as of Q3 2026.
  • Blue Trust sold 456 CONMED shares in Q3 2026, an estimated $20.9K.
  • CONMED made up ﹤0.01% of Blue Trust's portfolio in Q3 2026, its #657 holding.
  • Blue Trust first reported a position in CONMED in Q3 2022 and has held it in 17 quarters since.
  • Blue Trust's CONMED position peaked at $310K in Q1 2025.
  • 215 funds tracked by Wall St. Rank held CONMED as of Q3 2026.

Based on Blue Trust's 13F filing for Q3 2026, filed 15 Oct 2026.